In This Issue

---

• From the Editor: A note from Course Director, Dr. Christine Pellegrino, describing the content of Issue No. 3
• Faculty Biographies
• Pretest: Pretest must be completed before continuing with activity.
• Feature Article: Progress in Renal Cell Carcinoma: Historical Perspective and Targeted Therapies Dr. Janice P. Dutcher reviews state-of-the-art strategies and medications in treating renal cell carcinoma and describes future directions in drug research
• Expert's Perspective: How Teleoncology Is Changing Cancer Care in the Community Setting Dr. Anna Maria López describes how telemedicine is changing the practice of rural oncology, and how the University of Arizona shares its facilities via computer-based interaction
• Medical E-Practice: Metastatic Renal Cell Cancer with Multiple Risk Factor Profile Dr. Janice P. Dutcher offers an interactive case to test your decision-making skills in the treatment of a patient with advanced renal cell carcinoma and multiple risk factors
• The Oncology Library: Highlights from the Literature
• Posttest and Evaluation: Obtain CME after reading these articles by completing the CME Test and Evaluation Form

---

Additional Resources

---

Oncology Advantage: Resources for Staying Up to Date in Oncology

Learn about web-based resources and national/regional organizations that can help you with information and support in your practice of clinical oncology

Write to Us

---

Overview

---

Statement of Need

Community oncologists have a need for timely information on research advances and emerging technologies, as well as greater access to new therapies. In addition, there is a need for updated information on how to utilize innovative therapies and effectively manage their side effects in a rural practice environment.

Program Goal

Advances in Science and Practice in Rural Oncology will provide depth and perspective to the most important scientific findings, facilitating the application of research results to patient care. This on-line interactive newsletter provides the means to address the particular challenges and barriers common to oncology practice in rural environments. This activity is designed to increase the likelihood that rural cancer patients receive the most current evidence-based treatment and achieve longer survival.

Learning objectives

At the end of this activity, participants should be able to:

1. Provide care to oncology patients in accordance with current guidelines and protocols for different cancer types
2. Incorporate newer treatments into cancer management based on the latest scientific evidence
3. Manage side effects of chemotherapy
4. Evaluate the specific challenges of oncologists who practice in rural environments to maximize access to medical, surgical, and technical resources to improve patient care and outcomes

After completing issue 3, you should be able to:

1. Optimally treat patients with metastatic renal cell carcinoma (RCC) based on current standards of care
2. Recognize the role of new, targeted biologic agents in RCC treatment
3. Determine patient prognosis based on key risk factors

Privacy Policy

View privacy policy

Continuing Education Credit:

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine and In 2 MedEd. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement:

Albert Einstein College of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclaimer:

The opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine (sponsor), (Pfizer Inc.) or (In 2 MedEd). Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Copyright:

Albert Einstein College of Medicine owns the copyright of this CME activity on the Internet.

Contact Information:

For questions regarding CME, email cme@montefiore.org

For technical questions, email amadeus@amadeusmultimedia.com

editorial board

Course Director
Christine M. Pellegrino, MD
Assistant Professor of Medicine
Albert Einstein College of Medicine
Attending Physician,
Department of Medical Oncology
Montefiore Medical Center
Bronx, New York
Disclosure: Speakers Bureau: Amgen, Pfizer, sanofi-aventis, Genomic Health
Bio

Community Practice Editor
Thanjavur S. Ravikumar, MD
Chief Quality Officer, Surgery & Interventional Procedures
Director, Center for Surgical Innovation
PI/Medical Director, NCI Community Cancer Centers Program
Geisinger Health System
Danville/Wilkes Barre, Pennsylvania
Disclosure: Nothing to disclose
Bio

Guest faculty

Guest Editor
Janice P. Dutcher, MD
Attending Physician,
St. Lukes-Roosevelt Hospital
Director of Immunotherapy Program
Continuum Cancer Centers
New York, New York
Chair, Eastern Cooperative
Oncology Group, Renal Cancer Subcommittee
Professor, New York Medical College
Valhalla, New York
Disclosure: Research grant: Pfizer, Genentech, Exelixis
Speaker’s Bureau: Pfizer, Novartis, Genentech
Consultant: Genentech, Exelixis
Other: Bristol-Myers Squibb
Bio

Contributing Editor
Ana Maria López, MD, MPH, FACP
Associate Dean for Outreach and Multicultural Affairs,
Professor of Medicine and Pathology
Medical Director,
Arizona Telemedicine Program
Arizona Cancer Center
University of Arizona
Tucson, Arizona
Disclosure: Nothing to disclose
Bio

Planner Disclosures

Maxine Losseff
In 2 MedEd, LLC.
Nothing to Disclose

Barbara Saldinger
In 2 MedEd, LLC.
Nothing to Disclose

Joan Weiss
In 2 MedEd, LLC.
Nothing to Disclose

Einstein Disclosures
Nothing to Disclose